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The Aurora B kinase activity is required for the
maintenance of the differentiated state of murine
myoblasts
G Amabile1,2, AM D’Alise1, M Iovino1, P Jones3, S Santaguida4, A Musacchio4, S Taylor5 and R Cortese*,1
Reversine is a synthetic molecule capable of inducing dedifferentiation of C2C12, a murine myoblast cell line, into multipotent
progenitor cells, which can be redirected to differentiate in nonmuscle cell types under appropriate conditions. Reversine is also
a potent inhibitor of Aurora B, a protein kinase required for mitotic chromosome segregation, spindle checkpoint function,
cytokinesis and histone H3 phosphorylation, raising the possibility that the dedifferentiation capability of reversine is mediated
through the inhibition of Aurora B. Indeed, here we show that several other well-characterized Aurora B inhibitors are capable of
dedifferentiating C2C12 myoblasts. Significantly, expressing drug-resistant Aurora B mutants, which are insensitive to reversine
block the dedifferentiation process, indicating that Aurora B kinase activity is required to maintain the differentiated state. We
show that the inhibition of the spindle checkpoint or cytokinesis per se is not sufficient for dedifferentiation. Rather, our data
support a model whereby changes in histone H3 phosphorylation result in chromatin remodeling, which in turn restores the
multipotent state.
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Lineage-restricted cells can be reprogramed to a state
of pluripotency by several different manipulations, including
somatic cell nuclear transfer1 embryonic stem cell (ES)
fusion 2 or even by cotransfection of four specific transcription
factors. 3–5 In particular, C2C12 myoblasts can be repro-
gramed to dedifferentiate into multipotent progenitor cells
that can be redirected to other cell types under appropriate
stimuli, including the ectopic expression of Msx1 gene,6
or by exposure to chemical compounds such as
reversine.7
Reversine, a purine derivative, was identified by virtue of its
ability to increase the plasticity of C2C12 myoblasts. This
compound interferes with the normal differentiation pathway
causing C2C12 cells to dedifferentiate to a pluripotent state.
More recently, it was demonstrated that reversine can
differentiate human fibroblasts into skeletal muscle cells in
vitro and in vivo,8 suggesting that reversine is capable of also
reprograming primary somatic cells to a state of increased
plasticity. We recently discovered that reversine is also a
potent Aurora kinase inhibitor.9 The Auroras are serine/
threonine kinases required for multiple aspects of mitosis in
eukaryotic cells. Aurora A promotes centrosome maturation
and spindle assembly,10 whereas Aurora B is required for
histone H3 phosphorylation, chromosome segregation,11 the
spindle assembly checkpoint and cytokinesis.12
Evidence is emerging that the role of Aurora B is not
restricted to mitosis and cell division. A key substrate of
Aurora B is serine 10 (ser10) of histone H3, and although this
phosphorylation event was originally thought to be involved in
chromosome condensation, it now appears that it dissociates
HP1 proteins from methylated histone H3 (K9me3) at the
onset of mitosis.13,14 Indeed, histone H3 (ser10) is an
important element in the combinatorial histone code that is
associated with both active and inactive chromatin.15 At the
onset of mitosis, phospho-Ser10-H3 is responsible for the
ejection of HP1 proteins from their binding site on chromatin,
probably through a steric hindrance.13,14 Furthermore, it was
demonstrated that the modifications of histone H3 and
consequently the redistribution of HP1s are linked to
chromatin reorganization and to cellular dedifferentation.16
Consistent with a role for Aurora B in chromatin structure, it
was recently shown that Aurora B is required to remodel
chromatin during postmitotic cell differentiation of mesen-
chymal stem cells and in the transition of B cell to plasma cells.17
The ability of reversine to both dedifferentiate C2C12 cells
and to inhibit Aurora B raised the possibility that its
dedifferentiation capability is mediated through Aurora B.
Here, we present the evidence that in addition to reversine,
several other Aurora B inhibitors can dedifferentiate C2C12
myoblasts. By using drug-resistant Aurora B mutants, we
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provide compelling evidence that the effects of reversine are
mediated through Aurora B as opposed to an off-target effect.
Furthermore, we demonstrate that reversine remodels the
chromatin associated with several genes that are induced or
repressed during the phenomenon of dedifferentiation.
Altogether, our data suggest a novel role for the Aurora B
kinase in gene regulation and in the maintenance the
differentiated state.
Results and Discussion
Aurora kinase inhibitors reprogram C2C12 myo-
blasts. Reversine inhibits several proteins including MEK1,
nonmuscle myosin II (NMMII), Aurora A and B.9 On the basis
of several indirect lines of evidence, it was suggested that
reversine induces dedifferentiation by the simultaneous
inhibition of MEK1 and of NMMII.18 However, as reversine
is a potent Aurora inhibitor, we wanted to determine whether
the inhibition of Aurora A and/or B may be involved in the
dedifferentiation process. To do this, we asked whether a
panel of other Aurora kinase inhibitors could dedifferentiate
C2C12 cells, reasoning that structurally diverse inhibitors
should have different spectra of off-target effects.19 We
chose to use hesperadin, which is relatively selective for
Aurora B,20 VX-680, which is a dual Aurora A/B inhibitor21
and MLN-8054, which is relatively selective for Aurora A.22
Significantly, hesperadin, VX-680 and MLN-8054 induced
dedifferentiation of C2C12 myoblasts (Figure 1). C2C12 cells
were treated with compounds for 72 h as indicated; after this,
the drug-containing media were removed and the cells were
cultured in drug-free medium suitable for the development of
adipocytes (adipogenic-differentiating medium; ADM) and
osteoblasts (osteogenic-differentiating medium; ODM),
respectively. After 7 days, cells were stained with Oil Red
O reagent to evaluate the presence of adipocytes or for
alkaline phosphatase to evaluate the presence of osteoblasts
(Figure 1a). In addition, to have a quantitative analysis of the
dedifferentiation phenomenon, we used a fluorescent
substrate system to evaluate the amount of lipid droplets in
the case of adipocytes and the alkaline phosphatase activity
in the case of osteoblasts (Figure 1b, see Materials and
Methods also).
Furthermore, we decided to investigate also the expression
of specific markers of both osteoblast and adipocyte
differentiation. In particular, after the treatment with 500 nM
R
FU
ALP activity
0
500
1000
1500
2000
2500
3000
3500
4000
4500
Control VX-680Reversine Hesperadin
O
il  
Re
d 
st
ai
ni
ng
AL
P 
st
ai
ni
ng
72 hr treatment (500 nm)
Adipo Red assay
R
FU
0
2000
4000
6000
8000
10000
12000
72 hr treatment (500 nm)
0
500
1000
1500
2000
2500
3000
3500
4000
4500
72 hr treatment (50 nm)
0
2000
4000
6000
8000
10000
72 hr treatment (500 nm) 72 hr treatment (50 nm)
Con
trol
Rev
ersi
ne
Hes
per
adin
VX
-68
0
ML
N 8
054
Con
trol
Rev
ers
ine
Hes
per
adin
VX
-68
0
ML
N 8
054
Con
trol
Rev
ers
ine
Hes
per
adin
VX
-68
0
ML
N 8
054
Con
trol
Rev
ers
ine
Hes
per
adin
VX
-68
0
ML
N 8
054
Figure 1 Aurora kinases inhibitors induce C2C12 dedifferentiation. (a) C2C12 cells were treated for 72 h with 500 nM of reversine, hesperadin and VX-680. Alkaline
phoshatase and Oil Red O stainings were performed after 7 days of exposure to osteogenic-differentiating (ODM) and to adipogenic-differentiating media (ADM), respectively.
The arrows indicate cells positive for Alkaline phosphatase (upper panel) and for lipid droplets content (lower panel) (b) C2C12 cells were treated for 72 h with 500 or 50 nM of
reversine, hesperadin, VX-680 and MLN-8054. Then, cells were cultured in ODM and ADM media as indicated. ALP activity of C2C12 cells after the treatment was assayed
using a fluorescent substrate system and the results were expressed in relative fluorescence units (RFUs). Quantitative analysis of adipocyte differentation was assayed with
AdipoRed reagent to evaluate the lipids droplets content. The histograms show the RFUs measured with excitation at 485 nm and an emission at 572 nm
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of each compound and the exposure for 1 week to
differentiating media, we analyzed the expression of osteo-
pontin and collagen type 1 for the osteoblasts and the
expression of the adipocyted fatty acid-binding protein (ap2)
and of lipoprotein lipase (LPL) for the adipocytes. In Figure 2,
we show that the treatment with the Aurora kinase inhibitors
caused a relevant increase of these markers strengthening
the notion that reversine-treated myoblasts can be induced to
differentiate into other cell types.
Among the Aurora kinase inhibitors tested, reversine and
hesperadin were very potent inducers of dedifferentiation,
whereas MLN-8054 and VX-680 were only active at sig-
nificantly higher concentration (Figure 1b). Interestingly,
reversine and hesperadin are low nanomolar inhibitors of
Aurora B kinase (S Santaguida and A Musacchio, unpub-
lished observations, and Figure 3), and their effect on cultured
cells is mainly because of the inhibition of Aurora B kinase. By
contrast, when using VX-680 and MLN-8054, on cultured
cells, the predominant phenotype from these drugs is the
appearance of monopolar spindles, a hallmark of Aurora A
inhibition (A Musacchio and S Santaguida, unpublished
observations, and Manfredi et al.22 and Girdler et al.23 Thus,
the spectrum of inhibitor potencies suggests that Aurora B
kinase rather than A might be the target of reversine in the
dedifferentiation program.
Importantly, although reversine inhibits MEK1 and
NMMII,18 hesperadin and VX680 are not particularly potent
against these two enzymes (Supplementary Figure 1),
indicating that the inhibition of MEK1 and NMMII is not
necessary for C2C12 dedifferentiation.
Drug-resistant Aurora B kinase mutants block the
dedifferentiation capabilities of reversine . The fact that
multiple inhibitors of Aurora B can dedifferentiate C2C12
cells is consistent with the notion that Aurora B activity is
required to maintain the myoblasts in the differentiated state.
However, although unlikely, we cannot rule out the possibility
that all these inhibitors share a common ‘off-target’ enzyme.
Therefore, to exclude this possibility, we set out to express
drug-resistant Aurora B mutants in C2C12 cells and ask
whether this expression blocked reversine-induced
dedifferentiation. We reasoned that if the dedifferentiation
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Figure 2 The use of Aurora kinases inhibitor induces the initiation of osteogenic and adipogenic program. (a) qRT-PCR for osteogenic (osteopontin and collagen type 1)
and (b) adipogenic (adipocyte fatty acid-binding protein and lipoprotein lipase) genes was performed on C2C12 cells treated with 500 nM reversine, VX-680 and hesperadine,
and then cultured in osteogenic-differentiating (ODM) and adipogenic-differentiating media (ADM) (as described in Materials and Method section). Genes mRNA levels were
normalized using GAPDH. Untreated C2C12 cells were used to calculate the fold enrichment
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capability of reversine was mediated through the inhibition of
Aurora B, the ectopic expression of a drug-resistant Aurora B
mutant should maintain the myoblast state despite the
presence of reversine. By contrast, if reversine effects were
through another target, the expression of the drug-resistant
Aurora B mutants should have no effect.
Recently, we have described two mutations in the active
site of Aurora B, namely G160V and Y156H, which render it
resistant to ZM447439, hesperadin, VX-680 and MLN-8054.23
On the basis of the 3D structure of the complex between
reversine and Aurora B,9 we reasoned that these mutants
should also be resistant to reversine. To prove this prediction,
we tested the ability of increasing concentrations of reversine
to inhibit the activity of recombinant wild-type (WT) human
Aurora B:INCENP IN-box complex, or of equivalent com-
plexes bearing the G160V (Figure 3a) or the Y156H mutation
(data not shown), using histone H3 as an in vitro substrate. In
agreement with our prediction, the G160V and Y156H
mutations conferred a B100-fold or higher resistance to
reversine compared with the WT enzyme (Figure3a, and data
not shown).
Next, we used these drug-resistant mutants to directly test
the role of Aurora B in the process of dedifferentiation induced
by reversine. We transiently transfected C2C12 cells at 30%
of confluence with plasmids encoding either for WT human
Aurora B or the Y156H and G160V mutants. After 48 h,
western blot analysis showed expression of the exogenous
Aurora B proteins (Figure 3b). In a parallel experiment, 48-h
post-transfection, 50 nM reversine was added for 72 h. We
observed that reversine efficiently dedifferentiated the non-
transfected controls as shown by the change of cell
morphology (Figure 4a). Significantly, C2C12 cells trans-
fected with the drug-resistant mutants did not acquire the
round morphology typical of the controls (Figure 4a). In
particular, a myotube formation assay was performed to better
investigate whether the mutant G160V was sufficient to inhibit
the dedifferentiation capabilities of reversine. After 72 h of
reversine treatment, the cells were kept in the same plate for 8
days replacing the medium each 48 h to permit the myotubes
formation. We observed that only the control cells and the
cells previously transfected with the resistant mutant were
able to form myotubes after reversine exposure. We found
that after the transfection with the mutant, about 70% of cells
gave rise myotubes. Not trasfected cells and cells trasfected
with Aurora B WT lost completely the myoblast shape, and
were not able to form myotubes (Figure 4a).
Furthermore, we also investigated whether the presence of
Aurora B, resistant to reversine, would inhibit the whole
dedifferentiation–redifferentiation process induced by rever-
sine. After 72 h of reversine treatment, cells were transferred
into the appropriate differentiation medium and cultured for 1
week. Remarkably, in the presence of both mutants,
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Figure 3 The Aurora B G160V mutant is resistant to reversine. Human Aurora B:INCENP IN-box wild-type (WT; upper panels) and G160V mutant (lower panel) were
incubated at 301C for 1 h with histone H3 as a substrate, the indicated growing concentrations of reversine, and [g-32P]-ATP. DMSO was used as control. The incorporation of
radioactive phosphate on histone H3 was visualized by autoradiography. (a) C2C12 cells were transfected with Aurora B WT, Aurora B Y156H and Aurora B G160V. The
presence of ectopic gene expression was assessed after 48 h post-trasfection by western blot analysis using both an anti-Myc-tag antibody and anti-Aurora B antibody. An
antiactin antibody was used as loading control. (b) C2C12 cells were transfected with Aurora B WT, Aurora B Y156H and Aurora B G160V as indicated. After 48 h, cells were
treated with reversine 50 nM for further 72 h and typical western blot was performed to evaluate the protein levels of ectopic genes
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reprograming of C2C12 myoblasts induced by reversine was
drastically reduced (Figure 4b). The simplest interpretation of
these results is that Aurora B kinase activity is essential for the
action of reversine. We observed that cells transfected with WT
Aurora B displayed only a partial abrogation of the reversine
effect, presumably because of a gene dosage effect.
Reversine induces polyploidy and spindle checkpoint
override at high concentration. The results presented so
far show that Aurora B kinase is a key player in the nuclear
reprograming induced by reversine. Aurora B is involved in
multiple mitotic functions, and therefore inhibiting its kinase
activity causes a variety of phenotype including chromosome
segregation failure, spindle checkpoint override and
impairment of cytokinesis. Taken together, these effects
result in polyploidy.24 In principle, it is conceivable that it is
the polyploidy itself, rather than the inhibition of Aurora B per
se, which is responsible for the dedifferentiation process.
However, we feel that this is unlikely: other agents, which
cause polyploidy, including the MEK1 inhibitor U0126 and the
NMMII inhibitor blebbistatin do not cause reprogramming
(data not shown). Moreover, reversine induces reprograming
at concentrations as low as 20–50 nM, whereas significant
polyploidy is only observed at higher concentration of
reversine (Figure 5a). Similar considerations are true also
for the effect on the spindle check point: SP600125, a potent
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Figure 4 Drug-resistant Aurora B kinase inhibits the dedifferentiation process showing positive evidence of differentiation. C2C12 cells were transfected with Aurora B wild
type (WT) and Aurora B G160V. After 48 h, cells were treated with reversine 50 nM for further 72 h and then cultured in growth medium for additional 8 days. (a) Myotubes
formation was observed for control cells, as well for the Aurora B G160V tranfected cells. C2C12 cells treated with reversine (not transfected) and cells transfected with Aurora
B WT did not show any evidence of terminal differentiation. (b) C2C12 cells were transfected with Aurora B WT, Y156H and G160V variants as indicated. After the treatment
(72 h), the cells were cultured in osteogenic-differentiating (ODM) and adipogenic-differentiating media (ADM) for 1 week. ALP activity and lipid droplets content were
measured to evaluate the presence of osteoblasts and adipocytes, respectively using a fluorescent substrate system. Data are expressed as relative fluorescence units (RFUs;
see Materials and Methods also). Values of RFUs were statistically different with (*Po0.05) and (**Po0.01)
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spindle checkpoint overrider does not induce reprograming,
and even reversine must be used at concentrations above
1mM to cause spindle checkpoint overriding in C2C12
myoblasts (Figure 5b and c).
On balance, therefore, we suspect that the role of Aurora B
in maintaining the differentiated state of C2C12 cells is not
linked to its mitotic functions. More likely, the direct involve-
ment of Aurora B on reversine-induced dedifferentiation is
based on its role in chromatin remodeling. Consequently, we
turned our attention to another key function of Aurora B,
namely histone H3 (Ser10) phosphorylation (phospho-Ser10-
H3) and a possible role in chromatin remodeling. As predicted
for a potent Aurora B inhibitor, reversine does indeed inhibit
phospho-ser10-H3 in C2C12 cells (Figure 6a). Furthermore,
the inhibitory effect of reversine is significantly reduced
following the expression of the drug-resistant Aurora B
mutants (Figure 6a) confirming that Aurora B is the bona fide
serine 10 kinase, at least in C2C12 cells.
Reversine induces remodeling of chromatin at the level
of muscle differentiation genes. Myogenesis is a complex
process regulated by muscle regulatory factors (MRFs) and
their inhibitors (Ids proteins).25 As reported by several
groups,26–28 ectopic expression of MRFs, such as MyoD or
myogenin, converts nonmuscle cells into muscle cells,
suggesting that these factors play a crucial role both in the
induction of muscle differentiation and in the maintenance of
the differentiated muscle phenotype. Reversine treatment
affects the expression of MRFs; in Figure 6b–c, we show an
evident downregulation of the mRNA levels coding for MyoD,
myogenin and myogenic factor-5 (Myf5) after reversine
treatment. Interestingly, we also observed that the
expression of Id1, a known inhibitor of myogenesis,25
increased considerably after the treatment (Figure 6b,
lower right panel). The treatment of myoblasts with the
other Aurora inhibitors also caused a relevant dowregulation
of MyoD and Myf5, although, on the other hand, appeared
the upregulation of the Id1 expression (Figure 6c),
suggesting a common mechanism of action for the three
drugs, most likely triggered by the inhibition of Aurora B
kinase. In fact, reversine treatment in the presence of Aurora
B kinase-resistant mutants did not lead to the downregulation
of MyoD expression compared with the untreated cells of
with cells trasfected with Aurora B WT (Figure 6b).
Apparently, Aurora B inhibitors and reversine can cause
not only the repression but also, with similar kinetics, the
activation of genes. To elucidate the putative common
molecular event that is at the core of both activation and
repression of genes, we analyzed by chromatin immuno-
precipitation (ChIP) histone modifications at the level of the
5
0
10
15
20
25
30
Ce
lls
 in
 M
ito
sis
(%
 of
 ce
lls
 pl
ate
d)
Nocodazol
Reversine
- + + + + +
- - 50 nM 100 nM 500 nM 1 M
Control Nocodazol
Nocodazol + reversine 1MNocodazol + reversine 50 nM
Control
2N
4N
Reversine 50 nM
2N
4N
Reversine 100 nM
2N
4N
Reversine 1 M
2N
4N
2N
4N
8N
Reversine 5 M
20x
60x 60x
20x
20x20x
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MyoD, Myogenin and Id1 promoters. In essence, at the level
of the repressed genes (MyoD and Myogenin), we observed
the expected inhibition of phospho-Ser10 but no other
reversine dependent change, neither in the overall H3
acetylation, nor methylation (Lys4 and Lys9 were analyzed;
Figure 7). Interestingly, but not surprisingly, the dual
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Figure 6 Reversine inhibits histone H3 phosphorylation on Ser10 and induces the downregulation of MRFs expression . (a) C2C12 trasfected with Aurora B mutants were
treated with 50 nM of reversine for 48 h. After the treatment, the Ser10-H3 phosphorylation status was analyzed by western blot. Anti-Myc and anti-Aurora antibodies were
used as transfection control, whereas actin was used as loaded control. (b) MyoD mRNA levels were evaluated in untreated cells, cells treated with reversine and in cells
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real-time PCR with Taqman (MyoD) and SYBR green technologies (Myogenin, Myf5 and Id1)
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modification of acetyl Lys14 and phospho-Ser10 that repre-
sent a marker of gene induction29 was drastically reduced in
the genes repressed by reversine (Figure 8). This result is in
agreement with the findings of Mal et al.,30 who reported that
the presence of phospho-Ser10 at the level of myogenin
promoter is a marker of active chromatin. Therefore, it is likely
that the reversine causes a decrease in the expression of the
myogenin and MyoD genes by inhibiting the phospho-Ser10-
H3. In contrast to the repressed genes, the pattern of histone
modification at the promoter level of the induced gene Id1 was
drastically changed following the treatment with reversine. We
not only observed the expected inhibition of phospho-Ser10
but also a significant increase of overall H3 acetylation as well
as a decrease of the Lys9 methylation.
In summary, it appears that the common feature after
treatment with reversine is the drastic reduction of phospho-
Ser10-H3 on all the promoters analyzed (Figure 7), as
expected for a potent Aurora B kinase inhibitor. Surprisingly,
inhibition of phospho-Ser10-H3 leads to opposite effects in Id1
gene (induction) and in MyoD and myogenin (repression).
Recently, Sabbattini et al.17 reported the results that are in line
with our observations. These authors described a new role of
Aurora B kinase in the repression of genes in postmitotic
differentiated cells. Specifically, they reported that phospho-
Ser10 could be a marker of gene repression. Here, We show
that the Id1 gene is induced as a consequence of Aurora
B inhibition, and the chromatin at the level of its promoter is
drastically remodeled with markers typical of active genes
(increase in acetylation, decrease of Lys9 methylation). It is
likely that Aurora B associates with different protein com-
plexes to mark active and repressed genes. In the future, it will
be important to elucidate the molecular bases for these gene-
specific effects.
Materials and Methods
Cell culture, treatment and transfection. C2C12 myoblasts (ATCC
Manassas, VA) were cultured in growth medium consisting of DMEM supplemented
with 2 mM glutamine, 100 IU/ml penicillin, 100mg/ml streptomycin (Invitrogen Corp.,
Carlsbad, CA) and 10% (v/v) FBS (HyClone, South Logan, UT). C2C12 cells were
treated with reversine, VX-680, hesperadin, MLN-8054 at a concentration range
from 20 nM to 5mM, whereas control cells were incubated with 0.01% DMSO.
Treatment was maintained for 48 and/or 72 h without the growth medium changes.
C2C12 cells were transiently transfected with Lipofectamine 2000 (Invitrogen) as
suggested by the manufacturer. The cells were screened for the presence of ectopic
gene expression after 48 h by western blot.
Kinase assays. Recombinant human Aurora B45–344 and human INCENP835–903
were expressed and purified as described previously.23 Kinase assays were carried out
in 30ml reaction mix containing 50mM ATP, 1 mM DTT, 1 mM Na3VO4, 5mCi [g-
32P]-
ATP, 5mg of histone H3 as substrate, 1ml DMSO or drugs dissolved in DMSO, and
5 nM of WT or G160V mutant Aurora B/INCENP. Reaction mixes were incubated for
1 h at 301C, quenched with SDS-loading buffer and resolved on 14% SDS-
polyacrylamide gel (SDS-PAGE). Incorporation of 32P was visualized by
autoradiography.
RNA preparation and quantitative analysis. Total RNA was prepared
from C2C12 cells by using Qiagen’s RNeasys midi kit (Qiagen Inc., Valencia, CA).
MyoD expression was assessed after the treatments as indicated using TaqMant
chemistry with the ABI 7700 Prism real-time PCR (RT-PCR) instrument (Applied
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Figure 7 Aurora B is involved in affecting chromatin status. Chromatin immunoprecipitation analysis was performed on C2C12 cells treated with reversine 50 nM.
Polyclonal antibodies against H3 acetylated at lysine 9 and 14, against phospho-Ser10-H3, against dymethil Lys 9-H3 and against dymethil Lys 4-H3 were used to precipitate
the protein–chromatin complex. The DNA was purified, and specific regions of mouse MyoD, Myogenin and Id1 promoters were analyzed using the real-time PCR (see
Materials and Methods). Rabbit IgG was used as control of the assay specificity (purple barr). Asterisks indicate the values of fold enrichment statistically different with
(*Po0.05) and (**Po0.01)
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Biosystems, Foster City, CA). The forward and reverse primer (200 nM) sequences
for mouse MyoD were 50-TTCTTCACCACACCTCTGACA-30 and 50-GCCGT
GAGAGTCGTCTTAACTT-3,0respectively, and the probe sequence (100 nM) was
50-ACAGCCGGTGTGCATTCCAA-30. Data analysis was performed using 18S as
internal standard. The forward and reverse primer sequences for mouse 18S
were 50-CGGCTACCACATCCAAGGAA-30 and 50-GCTGGAATTACCGCGGCT-3,0
respectively, and the probe sequence was 50- TGCTGGCACCAGACTTGCCCTC-30.
Mouse Myf5 and Myogenin were analyzed as reported previously,31 whereas Id1
was analyzed as reported by Gersbach et al.32 The expression was measured using
SYBR green chemistry with the ABI 7700 Prism RT-PCR instrument (Applied
Biosystems). The forward and reverse primer sequences of mouse Gapdh used as
internal standard were 50-GGAGATTGTTGCCATCAACGACC-30 and 50-GGTCAT-
GAGCCCTTCCACAATGC-3,0 respectively. Osteopontin, collagen type 1, ap2 and
LPL expressions were analyzed with SYBR green method as reported previously.18
Dedifferentiation assay. C2C12 cells were cultured in the presence of
reversine, VX-680, hesperadin, MLN-8054 as described. After 72 h of treatment,
compounds were removed and cells were cultured in (ADM or in ODM. Adipogenic-
inducing medium contained DMEM 10% FBS, 4.5 g/l glucose, 1mM
dexamethasone, 0.5 mM isobutylmethylxantine and 10 mg/ml insulin (Sigma-
Aldrich, St. Louis, MO), whereas osteogenic-inducing medium contained DMEM-
10% FBS, 50mg/ml ascorbic acid-2-phosphate, 0.1mM dexamethasone and 10 mM
b-glicerophosphate (Sigma). For hystochemical analysis, after 7 days of culture in
ADM or ODM, cells were fixed with 4% paraformaldehyde for 15 min and washed
twice with PBS. Cells were then incubated for 2 h with Oil Red O reagent (Sigma) to
evaluate the presence of adipocytes and with mixture of 0.1 mg/ml of naphthol
AS-MX phosphate (Sigma), 0.5% N,N-dimethylformamide, 2 mM MgCl2 and 0.6 mg/
ml of fast blue BB salt (Sigma) in 0.1 M Tris-HCl, pH 8.5, to evaluate the presence of
osteoblasts. Cells were examined by phase-contrast microscopy with DFC320
microscope (Leica Microsystems, Wetzlar, Germany). For quantitative analysis,
after being cultured for 7 days in ADM, cells were incubated with AdipoRed reagent
for 10 min. ALP activity was measured with a fluorescent substrate system
(AttoPhos AP; Promega, Madison, WI). After 7 days in ODM, cells were incubated
with AttoPhos Substrate (Promega, Madison, WI) for 15 min. Fluorescence was
measured as suggested by the manufacturer using Fusion Universal Microplate
Analyzer and Envision Microplate Analyzer (Perkin Elmer).
Western blot analysis. Cells were lysed in 50 mM Tris/HCl buffer, pH 8.0,
containing 150 mM NaCl, 1% Nonidet P-40, 2 mg/ml aprotinin, 1 mg/ml pepstatin,
2 mg/ml leupeptin and 1 mM Na3VO4. Equal amounts of extracted proteins (50 mg)
were loaded and separated on SDS-PAGE (Invitrogen), and then transferred onto a
nitrocellulose membrane (Schleicher & Schuell Biosciences, Sandford, ME).
Immunodetection was performed using the following primary antibodies: anti-
Myc-Tag and anti- ser10P-H3 (Millipore, Billerica, MA), antimouse Aurora B (Becton
Dickinson, San Jose, CA) and antimouse/human Aurora B (Abcam Inc.,
Cambridge, MA).
Cell cycle analysis. C2C12 cells were incubated with reversine as indicated
for 48 h, then the growth medium contained reversine was changed and the cells
were cultured with a medium suitable for the development of osteoblstasts (ODM)
for 96 h. Cells were fixed in 70% ethanol over night. After double washing with PBS,
cells were labeled with cell–cycle-staining reagent PBS/0.In all, 1% Triton X-100,
200mg/ml DNAse-free RNAse, 25 mg/ml propidium iodide (Invitrogen) and
incubated at room temperature, in the dark, for 30 min. DNA content was
analyzed using FACS Canto II (Becton Dickinson).
Immunofluorescence. In all, 5 104 cells were cultured on poly-lysine
(Sigma)-coated coverslips and incubated in the presence of nocodazol 500 nM and
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Figure 8 Reversine decreases drastically Ser10-H3 phoshorylation at levels of MRFs genes. Chromatin immunoprecipitation analsysis was performed on C2C12 cells
treated with reversine 50 and 500 nM as indicated. Polyclonal antibodies against H3 acetylated at lysine 9 and 14 and against anti-phospho-Ser10-acetyl (K14)-histone H3
were used to precipitate the chromatin—protein complex. The DNA was purified and specific regions of mouse MyoD and myogenin promoter were analyzed using the real-
time PCR (see Materials and Methods). Rabbit IgG was used as control of the assay specificity (purple barr). Values obtained for the fold enrichment were statistically different
with (*Po0.05) and (**Po0.01)
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reversine as indicated for 4 h. Cells were fixed in 4% paraformaldehyde for 20 min at
room temperature. After two washes with PBS, cells were stained with DAPI 0.5mg/
ml for 1 h. The samples were analyzed with Confocal Microscopy with LSM 510
META microscope (Zeiss, Thornwood, NY).
Chromatin immunoprecipitation. Cells (106 for each antibody) were used
to cross-link chromatin using the protocol from Upstate Biotechnology (Milton
Keynes, UK) with minor modifications. Briefly, cells were incubated in 1%
formaldehyde for 10 min at room temperature. Glycine (0.125 M) was added to stop
cross-linking. Cross-linked chromatin was sonicated three times for 10 s at 80%
amplitude (Vibra-Cell sonicator; Sonics and Materials, Meryin/Satigny, Switzerland).
Polyclonal antibodies raised against H3 acetylated at lysine 9 and 14 (aH3-Ac) and
against antiphospho-S10-acetyl (K14) histone H3, both from Millipore, whereas
antihistone H3 dymethil K4, antihistone H3 dymethil K9 and anti-phospho-Ser10-H3
were purchased from Abcam. DNA was purified by phenol–chloroform extraction,
and specific regions of the indicated promoters were amplified by RT-PCR using
SYBR green method (Applied Biosystem). The primers used for mouse MyoD
promoter were 50-CGCCCCCAGCCTCCCTTTCCA-30 and 50-TGTCAGAGGTG
TGGTGAAGAAA-30; mouse myogenin promoter was analyzed as reported
previously.30 The primers used to analyze the TATA box of mouse Id1 promoter
were 50-CTTATAAAAGACTGGCTCCAGC-30 and 50-GGAGGCTGAGAACA
GAAACAGAGTGTG-30 To calculate the fold enrichment, a previously published
method was used.33
Statistical analysis. Statistical analysis was performed by the analysis of
variance (ANOVA) test using Origin 6.1 software for Windows (Microcal Software
Inc., Northempton, MA).
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